echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Eli Lilly's third COVID-19 neutralizing antibody receives FDA emergency use authorization for Omicron

    Eli Lilly's third COVID-19 neutralizing antibody receives FDA emergency use authorization for Omicron

    • Last Update: 2022-05-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    Recently, Eli Lilly announced that its new crown neutralizing antibody bebtelovimab has been granted Emergency Use Authorization (EUA) by the FDA for the treatment of patients with mild to moderate new coronary pneumonia
    This is the third neutralizing antibody that Eli Lilly has obtained EUA.
    The other two are bamlanlvimab (banivirumab) imported from Abcellera and JS016 (etelvizumab) imported from Junshi Bio


    Bebtelovimab, a broad-spectrum neutralizing antibody introduced by Eli Lilly from Abcellera, has potent neutralizing activity against all currently known mutant strains, including the "Omicron" strain

    The authorization is based on data from a Phase II clinical BLAZE-4 trial (NCT04634409)
    This is a randomized, double-blind, placebo-controlled Phase II clinical study to evaluate the safety and efficacy of bebtelovimab alone or in combination in patients with mild to moderate COVID-19

    The results showed that 175mg bebtelovimab was comparable to bamlanvimab (700mg) + etesevimab (1400mg) + bebtelovimab (175mg) combination therapy in reducing viral titers in patients


    Not long ago, Eli Lilly had signed an order with the U.
    government for 600,000 doses of bebtelovimab neutralizing antibodies, with a total amount of up to $720 million


    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.